AWM
NRXP icon

AE Wealth Management’s NRX Pharmaceuticals NRXP Stock Holding History

AE Wealth Management’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,952
Closed -$32.8K – 1964
2022
Q4 		$32.8K Buy
+2,952
New +$29.7K ﹤0.01% 1770

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

AE Wealth Management's NRXP Position: Q1 2023 in Review

AE Wealth Management sold out of NRX Pharmaceuticals (NRXP) in Q1 2023, closing a stake of 2,952 shares — an estimated $32.8K sold.

AE Wealth Management first reported a position in NRXP in Q4 2022 and held it in 1 quarter. The position peaked at $32.8K in Q4 2022. 30 funds tracked by Wall St. Rank hold NRXP as of Q1 2023.

  • AE Wealth Management reported no remaining NRX Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • AE Wealth Management sold 2,952 NRX Pharmaceuticals shares in Q1 2023, an estimated $32.8K.
  • AE Wealth Management first reported a position in NRX Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • AE Wealth Management's NRX Pharmaceuticals position peaked at $32.8K in Q4 2022.
  • 30 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2023.

Based on AE Wealth Management's 13F filing for Q1 2023, filed 14 Apr 2023.